Company profile
Veru Inc.
NASDAQ: VERU · Healthcare · Biotechnology
#574 of 1,422 Healthcare companies by revenue46th-percentile growth
EA Score
49DFH 37DQ 69GM 41SS 60
v0.1 · 65/100 weight · provisional
↑ disclosure history, listing tenure · ↓ Piotroski F, 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$22.7M
Employees
20
as of 2026-08-19
Market cap
$41.6M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$16.9M$16.9M2024
Net income-$22.7M-$22.7M2025
Operating income-$24.8M-$24.8M2025
Total assets$29.8M$29.8M2025
Liabilities$11.5M$11.5M2025
Equity$18.3M$18.3M2025
Revenue trend
FY2018 – FY2024 · USD
FY18
FY19
FY19
FY20
FY21
FY22
FY23
FY24
Revenue by segment
Filed disclosures · FY2024
By product
Global public health sector86%
U.S. prescription channel14%
By geography
UNITED STATES32%
Other Geographical Areas28%
BRAZIL16%
MOZAMBIQUE13%
SOUTH AFRICA11%
The read
What is Veru Inc.’s revenue?
Veru Inc. booked $16.9M in FY2024 revenue, growing 3.6% year over year — about the middle of the pack among Healthcare companies we track, at a -134.6% net margin.
Peers · Healthcare
Vivos Therapeutics, Inc.38DClever Leaves Holdings Inc.——Choom Holdings Inc.——Pelthos Therapeutics Inc.37DIsodiol International Inc.——Inspire Veterinary Partners, Inc.——Neighbors
Miami-Dade →Key facts
CEOMitchell S. Steiner
SectorHealthcare
IndustryBiotechnology
HeadquartersMiami, FL
ExchangeNASDAQ: VERU
Employees20
IPO date1999-02-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.